Search Results
Jan 07, 2026, 07:37 ET First Mining Announces Socio-Economic Analysis for the Springpole Gold Project
included an analysis of the Project benefits. This analysis has been updated based on the recently announced updated Pre-Feasibility Study (the "PFS"). The Updated Analysis undertaken by WSP Canada Inc. demonstrates the major benefits to the local region around the Project, to Ontario and to Canada.
More news about: First Mining Gold Corp.
Jan 06, 2026, 21:50 ET Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study
P=0.019), with the survival benefit becoming more evident over time. It also reduced the risk of disease progression or death by 54% (PFS HR=0.46, P＜0.001), extending median PFS from 4.8 to 7.1 months.With a median follow-up of 32.5 months, the long-term safety profile of the ivonescimab combination
More news about: Akeso, Inc.
Jan 06, 2026, 13:32 ET Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
significant and clinically meaningful prolongation of progression-free survival (PFS) with approximately 35% reduction in the risk of disease progression or death versus trastuzumab plus chemotherapy. This resulted in a median PFS of more than one year, representing a greater than four-month improvement compared
More news about: Jazz Pharmaceuticals plc
Jan 05, 2026, 04:27 ET Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
PD-L1-positive NSCLC, demonstrated a statistically significant and clinically meaningful improvement in its primary endpoint of progression-free survival (PFS). A positive trend was also observed in overall survival (OS). OptiTROP-Lung05 is the first Phase III study of an immunotherapy and ADC combination to
More news about: Kelun-Biotech
Jan 02, 2026, 16:05 ET ADC Therapeutics Announces New Employee Inducement Grant
runway into at least 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue
More news about: ADC Therapeutics SA
Dec 28, 2025, 21:24 ET Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy
1. CX-5461 RP2D combined with PD-1 inhibitor2. Safety & tolerability for CX-5461 monotherapy & combination3. PFS in refractory MSS CRC with liver metastases for CX-5461 monotherapy & combination
More news about: Senhwa Biosciences, Inc.
Dec 23, 2025, 07:00 ET First Mining Files Pre-Feasibility Study Technical Report for the Springpole Gold Project, Ontario, Canada
Mineral Projects ("NI 43-101") and has an effective date of December 1, 2025.The 2025 PFS results support a 30,000 tonnes-per-day ("tpd") open pit mining operation.2025 PFS Highlights1,2US$3.2 billion pre-tax net present
More news about: First Mining Gold Corp.
Dec 22, 2025, 07:00 ET Defense Metals Provides Joint Letter to Shareholders from Executive Chairman and CEO
well positioned to execute its long-term strategy.A major milestone in 2025 was the completion of the Pre-Feasibility Study (PFS) for the Wicheeda Project. The PFS confirmed the Wicheeda Project as the only undeveloped rare earth project in North America and Europe with proven mineral reserves,
More news about: Defense Metals Corp.
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems annuncia la pubblicazione dei risultati dello studio PACE, che mostrano il valore clinico della conta delle cellule tumorali circolanti con CELLSEARCH® in uno specifico sottotipo di carcinoma mammario metastatico
Sebbene nella popolazione complessiva non sia stata osservata alcuna differenza significativa nella sopravvivenza libera da progressione (PFS) tra i gruppi di trattamento, le pazienti con malattia aggressiva (5 o più CTC) hanno mostrato una riduzione clinicamente rilevante del rischio di progressione
More news about: Menarini Silicon Biosystems
Dec 17, 2025, 18:49 ET U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
substitution mutations. The primary endpoint of the study is PFS (using RECIST v1.1 guidelines) as assessed by Blinded Independent Central Review (BICR). Secondary endpoints include OS, ORR, DoR, progression-free survival after first subsequent therapy (PFS2) and intracranial PFS.9Resistance
More news about: Johnson & Johnson
Dec 17, 2025, 18:33 ET INTEGRA DELIVERS ROBUST FEASIBILITY STUDY FOR DELAMAR GOLD-SILVER HEAP LEACH PROJECT HIGHLIGHTING IMPROVED ECONOMICS AND REDUCED DEVELOPMENT RISK
and processing: Two oxide heap leach facilities ("HLF") (vs. single large HLF design in the 2022 Pre-Feasibility Study ("PFS")), and two-stage crushing (vs. three-stage in PFS); reduced mine-site footprint and enhanced water usage strategy brings potential permitting advantages.Meaningful
More news about: Integra Resources Corp.
Dec 17, 2025, 06:30 ET Denison Announces Closing of Transaction with Skyharbour and Formation of Four Prospective Exploration Joint Ventures Proximal to Wheeler River
feasibility study was completed for the Phoenix deposit as an ISR mining operation, and an update to the previously prepared 2018 Pre-Feasibility Study ('PFS') was completed for Wheeler River's Gryphon deposit as a conventional underground mining operation. Based on the respective studies, both deposits have
More news about: Denison Mines Corp.
Dec 16, 2025, 16:01 ET Collective Mining Expands Ramp Zone by Drilling its Highest Grade Intercept Ever at Apollo: 24.80 Metres @ 29.42 g/t Gold Within 63.90 Metres @ 13.46 g/t Gold from 388.25 Metres
Lower Mine is derived from the NI 43-101 compliant technical report titled "Technical Report for the Marmato Gold Mine, Caldas Department, Colombia, PFS of the Lower Mine Expansion Project," with an effective date of June 30, 2022 (filed November 23, 2022). This report is available on Aris Mining Corporation's
More news about: Collective Mining Ltd.
Dec 16, 2025, 08:00 ET Wealth Enhancement Announces Acquisition of Spectrum Wealth Management and Associated Tax Practice
financial professionals, and five support staff oversees more than $182 million in client assets and is led by Benjamin Ross Putman, CPA, CFP®, CEPA, PFS, CDFA, Founder and Principal, Sanaz Afshar, CPA, Joseph Reese, CPA, and Allan Ottens, CPA.
More news about: Wealth Enhancement
Dec 15, 2025, 23:55 ET Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
progression-free survival (CNS-PFS) of 15 months. The results of another Phase II clinical study of utidelone combined with bevacizumab for HER2-negative BCBM were published in JAMA Oncology in 2025 [2]. 47 subjects were recruited in the study, with a CNS-ORR of 42.6%, a median CNS-PFS of 10.6 months,
More news about: Biostar Pharma, Inc.
Dec 12, 2025, 11:45 ET Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
patients with ESR1-mutated diseaseIn all patients, the imlunestrant plus abemaciclib combination achieved a median PFS of 10.9 months, demonstrated a favorable OS trend, and extended time to chemotherapy by more than a yearThese data were
More news about: Eli Lilly and Company
Dec 12, 2025, 10:47 ET Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
progression-free survival of 7.2 months in second-line MTAP-del pancreatic cancer patients, along with a 49% overall response rate and 9.1 months median PFS in a histology-selective cohort of 13 late-line difficult-to-treat cancer types. The company secured $225 million in gross proceeds from an October 2025
More news about: USA News Group
Dec 12, 2025, 08:27 ET ARIS MINING CLOSES ACQUISITION OF REMAINING 49% OF SOTO NORTE
gold project, where a new Preliminary Economic Assessment has been completed and a Prefeasibility Study is in progress. Following completion of the PFS, Toroparu will be positioned to advance toward construction.Aris Mining also owns the Soto Norte gold project, where a Prefeasibility Study has
More news about: Aris Mining Corporation
Dec 11, 2025, 17:31 ET Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight
combination remained alive and progression-free compared to just 29.7% in the control arm, with a median PFS not yet reached in the treatment group versus 18.1 months in controls.Beyond PFS, the data demonstrated sustained benefits across secondary endpoints. Complete response rates of 81.8% were
More news about: DelveInsight Business Research, LLP
Dec 11, 2025, 06:00 ET IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
Targeted enrollment of 435 patients to enable potential full approval filing has been completed in OptimUM-02 trialTopline data, including median PFS, are expected in 1Q 2026 to support a potential accelerated approval filing in the United StatesSOUTH SAN
More news about: IDEAYA Biosciences, Inc.
Dec 10, 2025, 20:53 ET Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
median progression-free survival (mPFS) was 15.2 months, with a 12-month PFS rate of 56.3%.In the CPS≥10 subgroup, the ORR was 83.3%, the DCR was 100%, the mDOR was 12.2 months; the mPFS was 15.9 months, with a 12-month PFS rate of 66.7%.In the CPS<10 subgroup, the ORR was 79.3%, the
More news about: Akeso, Inc.
Dec 10, 2025, 14:02 ET Menarini Group presenta datos de combinación de fase 2 de Elacestrant (ORSERDU®) en pacientes con cáncer de mama metastásico (CMM) ER+, con HER2 en el Simposio de Cáncer de Mama 2025 en San Antonio
SABCS demuestran que elacestrant en combinación con everolimus o con abemaciclib muestra un beneficio uniforme de supervivencia libre de progresión (PFS, por sus siglas en inglés), independientemente del estado de la mutación ESR1 en pacientes con CMM con ER+/HER2-, que experimentan progresión
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 06:15 ET Uranium Energy Corp Reports Results for First Quarter of Fiscal 2026
2025, targeting conversion of inferred to indicated uranium estimated resources to support the previously announced proposed pre-feasibility study ("PFS") for the world-class, high-grade Roughrider Project in the prolific Athabasca Basin of Saskatchewan, Canada.Launched United States
More news about: Uranium Energy Corp
Dec 09, 2025, 23:19 ET Il Gruppo Menarini presenta i dati di fase 2 sulla combinazione di elacestrant (ORSERDU®) in pazienti affetti da carcinoma mammario metastatico (mBC) ER+, HER2- al Simposio sul cancro al seno di San Antonio del 2025
saranno presentati al SABCS dimostrano che elacestrant, in combinazione con everolimus o con abemaciclib, mostra un beneficio costante in termini di PFS, indipendentemente dallo stato di mutazione ESR1 nei pazienti affetti da mBC ER+/HER2-, che presentano progressione della malattia durante la
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 14:24 ET Menarini Group 於 2025 年聖安東尼奧乳癌研討會公佈 Elacestrant (ORSERDU®) 針對 ER+、HER2- 轉移性乳癌 (mBC) 患者的第 2 期聯合治療數據
聯合使用的安全性特徵，與每種藥物已知的安全性特徵一致。並未發現新的安全訊號。」將於 SABCS 發表的 ELEVATE 數據顯示，對於曾在接受內分泌治療 (ET) 後病情惡化（不論是否曾使用 CDK4/6 抑制劑）的 ER+/HER2- mBC 患者，elacestrant 聯合 everolimus 或 abemaciclib 均顯示出一致的 PFS 效益，且不受 ESR1 突變狀態影響。最新結果亦顯示，聯合療法的安全性與各標靶療法加上標準護理內分泌療法的已知安全性一致。第 2 期 mPFS（月）（95% 置信區間 [CI]），涵蓋所有患者及亞組
More news about: Menarini Industrie Farmaceutiche Riunite